Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rigel Pharmaceuticals excels in sales, faces awareness challenges ahead

Rigel Pharmaceuticals demonstrated strong sales performance and efficient cost management in Q4 2022.
The company faces challenges in raising awareness, maintaining persistency, and reaching profitability.
Exploring market opportunities, partnerships, and collaborations position Rigel for future growth.
Competitive trial results and a focus on persistency drive Rigel's competitive edge in the market.

Rigel Pharmaceuticals excels in Q1 with REZLIDHIA and TAVALISSE, faces prescribing behavior challenges

Rigel Pharmaceuticals showcased strong Q1 performance, particularly with REZLIDHIA and TAVALISSE, while facing challenges in understanding prescribing behavior.
The company's focus on differentiated positioning, academic-community growth, and strategic partnerships presents promising opportunities for future expansion.
Financial stability, positive clinician feedback, and ongoing pipeline advancements position Rigel well for continued growth and success in the market.

Rigel Pharmaceuticals reports robust Q2 sales and strategic growth focus

Rigel Pharmaceuticals showcased strong sales performance and product efficacy in Q2, positioning for future growth.
Challenges in managing expenses and strategic decision-making require careful navigation for sustained profitability.
Exploration of new opportunities and continued focus on innovation present avenues for revenue growth and market expansion.
Financial stability, ongoing development programs, and positive market feedback underpin Rigel's strategic direction and growth potential.

Rigel Pharmaceuticals excels in Q3 sales, eyes pipeline expansion

Rigel Pharmaceuticals demonstrated robust sales growth in Q3, managed expenses effectively, and aims for financial breakeven through operational efficiency. The company's strategic focus on pipeline expansion and partnerships positions it well for future growth and innovation.

Rigel Pharmaceuticals posts record sales, eyes growth with Gavreto acquisition

Rigel Pharmaceuticals reported strong financial performance with record sales and net income in Q4 2023.
The acquisition of Gavreto presents growth opportunities in the oncology market.
Challenges include transitioning Gavreto to commercial operations and competition in the targeted therapy space.

Rigel Pharmaceuticals reports strong Q1 performance and growth opportunities

Rigel Pharmaceuticals demonstrated strong performance in Q1 2024 with robust demand for key products and strategic acquisitions.
While facing challenges such as inventory management and financial breakeven, the company is well-positioned for growth.
Opportunities lie in continued sales growth, clinical advancements, and portfolio expansion through in-licensing deals.

Rigel Pharmaceuticals excels in Q2 with strong sales and pipeline progress

Rigel Pharmaceuticals delivered a robust performance in Q2 2024, driven by commercial success, pipeline advancements, and financial discipline. While facing challenges in clinical trial strategies and competitive landscape, the company is well-positioned to capitalize on growth opportunities through product expansions and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL) that data submitted in May from fostamatinib Phase 2 trial for COVID-19 is insufficient for an emergency use authorization (EUA). Rigel submitted clinical data from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib for hospitalized COVID-19 patients.

Rigel Stock Falls After Update From COVID-19 Program

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time.

Rigel Pharmaceuticals Provides Update on COVID-19 Program

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Aug. 3, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline

SOUTH SAN FRANCISCO, Calif., July 27, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2021 financial results after market close on Tuesday, August 3, 2021.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update

BioCryst Pharmaceuticals

Eli Lilly

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

3 Biotech Stocks That Could Rocket Higher

SOUTH SAN FRANCISCO, Calif., July 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place online from July 17 – 21, 2021.

New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Advaxis

Second Sight Medical Products

SenesTech

Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?

Top Biotech Penny Stocks to Buy This Week? 9 To Watch

SOUTH SAN FRANCISCO, Calif., June 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health (NIH) ACTIV-4 (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial in hospitalized patients with COVID-19.

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

Senmiao Technology

Asensus Surgical

BEST Inc - ADR

CYREN

iQSTEL Inc.

Iterum Therapeutics Plc

Looking for penny stocks to buy in July 2021? Here's 7 for your watchlist The post Top Penny Stocks to Buy in July?

Top Penny Stocks to Buy in July? 7 You May Not Know About

Rigel Pharmaceuticals: A Patented FDA Approved Drug That May Successfully Fight COVID-19

SOUTH SAN FRANCISCO, Calif., May 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m.

Rigel to Present at the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L.

Rigel Appoints Alison L. Hannah, M.D.

The stock price of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) increased from 11.82% (from $3.47 to $3.88) pre-market. This is why it happened.

RIGL Stock: 11.82% Increase (From $3.47 To $3.88) Pre-Market Explanation

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q1 2021 Results - Earnings Call Transcript

Rigel (RIGL) delivered earnings and revenue surprises of 2100.00% and 102.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Tops Q1 Earnings and Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Rigel Reports First Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021.

Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

Rigel Pharmaceuticals has four value drivers that could generate substantial revenue growth and have limited downside risk. It appears as if the market has failed to recognize the potential upside. TAVALISSE continues to gain commercial traction in chronic ITP and has the potential to be a market leader in wAIHA and contribute to the battle against COVID-19.

Rigel Pharmaceuticals: Escalating Value Drivers Improve Upside Potential

The company announced positive results from an important COVID-19 clinical study.

Why Rigel Pharmaceuticals Stock Jumped Today

The stock price of Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) increased by over 15% pre-market. This is why it happened.

RIGL Stock: Over 15% Increase Pre-Market Explanation

SOUTH SAN FRANCISCO, Calif., April 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19.

Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19

SOUTH SAN FRANCISCO, Calif., April 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.

News for Rigel Pharmaceuticals Stock (RIGL)